FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961567422> ?p ?o ?g. }

• W2961567422 endingPage "3120" @default.
• W2961567422 startingPage "3111" @default.
• W2961567422 abstract "Diffuse large B‐cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. Diagnostic tools in the clinic can now identify distinct subsets characterized by unique molecular features, which are increasingly transforming how these patients are managed. Activated B–cell‐like DLBCL is characterized by NF‐κB activation and chronic B‐cell receptor signaling and may be targeted with lenalidomide or ibrutinib in the relapsed setting. Germinal center‐like DLBCL is enriched for activating EZH2 mutations, and encouraging activity has been observed for the EZH2 inhibitor tazemetostat, which now has a fast‐track US Food and Drug Administration designation. Double‐hit lymphoma is a high‐grade B‐cell lymphoma characterized by translocations of MYC and BCL2 and/or BCL6 and carries a poor prognosis. Intensive chemoimmunotherapy strategies appear to be superior to standard R‐CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone) as initial therapy, and anti‐CD19 chimeric antigen receptor T cells are inducing remission in patients with relapsed/refractory disease who previously had few available options. Primary mediastinal (thymic) large B‐cell lymphoma is a molecularly distinct large‐cell lymphoma with clinical and molecular features that overlap with those of classical Hodgkin lymphoma. R‐CHOP has been associated with an unacceptably high rate of primary treatment failure in this young population, whereas dose‐adjusted EPOCH‐R (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab) produces durable remissions without the need for radiotherapy in most patients. For relapsed/refractory disease, immune checkpoint inhibitors targeting PD‐1 have shown promising activity in chemotherapy‐refractory disease, as have anti‐CD19 chimeric antigen receptor T cells. Additional therapeutic targets, including JAK2, continue to be evaluated. The identification of discrete biological subsets is steadily moving us away from a “one‐size‐fits‐all” approach in DLBCL." @default.
• W2961567422 created "2019-07-23" @default.
• W2961567422 creator A5002103749 @default.
• W2961567422 date "2019-07-09" @default.
• W2961567422 modified "2023-10-16" @default.
• W2961567422 title "Hitting back at lymphoma: How do modern diagnostics identify high‐risk diffuse large B‐cell lymphoma subsets and alter treatment?" @default.
• W2961567422 cites W1020989877 @default.
• W2961567422 cites W1543770336 @default.
• W2961567422 cites W1978932947 @default.
• W2961567422 cites W1982834279 @default.
• W2961567422 cites W1986354050 @default.
• W2961567422 cites W1994719395 @default.
• W2961567422 cites W2001196047 @default.
• W2961567422 cites W2024373518 @default.
• W2961567422 cites W2028850684 @default.
• W2961567422 cites W2030105242 @default.
• W2961567422 cites W2043622833 @default.
• W2961567422 cites W2056555760 @default.
• W2961567422 cites W2064223130 @default.
• W2961567422 cites W2090714945 @default.
• W2961567422 cites W2110372244 @default.
• W2961567422 cites W2120415962 @default.
• W2961567422 cites W2120572492 @default.
• W2961567422 cites W2125616358 @default.
• W2961567422 cites W2128627706 @default.
• W2961567422 cites W2139836848 @default.
• W2961567422 cites W2143118351 @default.
• W2961567422 cites W2152006714 @default.
• W2961567422 cites W2153422981 @default.
• W2961567422 cites W2153944703 @default.
• W2961567422 cites W2158267770 @default.
• W2961567422 cites W2160848167 @default.
• W2961567422 cites W2168681651 @default.
• W2961567422 cites W2173798589 @default.
• W2961567422 cites W2216659987 @default.
• W2961567422 cites W2310716991 @default.
• W2961567422 cites W2376907976 @default.
• W2961567422 cites W254931162 @default.
• W2961567422 cites W2553748298 @default.
• W2961567422 cites W2582696216 @default.
• W2961567422 cites W2594602128 @default.
• W2961567422 cites W2600581432 @default.
• W2961567422 cites W2601571543 @default.
• W2961567422 cites W2605009867 @default.
• W2961567422 cites W2609973112 @default.
• W2961567422 cites W2610797169 @default.
• W2961567422 cites W2612422239 @default.
• W2961567422 cites W2617968907 @default.
• W2961567422 cites W2621746631 @default.
• W2961567422 cites W2622248280 @default.
• W2961567422 cites W2625473279 @default.
• W2961567422 cites W2734515449 @default.
• W2961567422 cites W2746315886 @default.
• W2961567422 cites W2751075585 @default.
• W2961567422 cites W2773804840 @default.
• W2961567422 cites W2797292560 @default.
• W2961567422 cites W2797584152 @default.
• W2961567422 cites W2801763724 @default.
• W2961567422 cites W2807906520 @default.
• W2961567422 cites W2811139677 @default.
• W2961567422 cites W2843787264 @default.
• W2961567422 cites W2892326722 @default.
• W2961567422 cites W2894397394 @default.
• W2961567422 cites W2903062212 @default.
• W2961567422 cites W2903278833 @default.
• W2961567422 cites W2903962322 @default.
• W2961567422 cites W2906129219 @default.
• W2961567422 cites W94592798 @default.
• W2961567422 doi "https://doi.org/10.1002/cncr.32145" @default.
• W2961567422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31287161" @default.
• W2961567422 hasPublicationYear "2019" @default.
• W2961567422 type Work @default.
• W2961567422 sameAs 2961567422 @default.
• W2961567422 citedByCount "14" @default.
• W2961567422 countsByYear W29615674222019 @default.
• W2961567422 countsByYear W29615674222020 @default.
• W2961567422 countsByYear W29615674222021 @default.
• W2961567422 countsByYear W29615674222022 @default.
• W2961567422 crossrefType "journal-article" @default.
• W2961567422 hasAuthorship W2961567422A5002103749 @default.
• W2961567422 hasBestOaLocation W29615674221 @default.
• W2961567422 hasConcept C126322002 @default.
• W2961567422 hasConcept C143998085 @default.
• W2961567422 hasConcept C2776694085 @default.
• W2961567422 hasConcept C2776755627 @default.
• W2961567422 hasConcept C2777938653 @default.
• W2961567422 hasConcept C2778461978 @default.
• W2961567422 hasConcept C2778559949 @default.
• W2961567422 hasConcept C2779338263 @default.
• W2961567422 hasConcept C2779429289 @default.
• W2961567422 hasConcept C2779725641 @default.
• W2961567422 hasConcept C2779878957 @default.
• W2961567422 hasConcept C2780653079 @default.
• W2961567422 hasConcept C2908647359 @default.
• W2961567422 hasConcept C502942594 @default.
• W2961567422 hasConcept C71924100 @default.
• W2961567422 hasConcept C99454951 @default.
• W2961567422 hasConceptScore W2961567422C126322002 @default.

• next